The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241258164 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Yanmeng Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Neoadjuvant Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was supported by grants from the 345 Talent Project of Shengjing Hospital and National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
This study aimed to analyze the efficacy and safety of neoadjuvant and adjuvant immunotherapies for non-small cell lung cancer (NSCLC).
Methods
Electronic literature searches were conducted in PubMed, OVID, Web of SCI, Embase, Cochrane Library, and the Chinese National Knowledge Infrastructure databases. The deadline for literature update and retrieval is February 16, 2024. Studies presented at meetings were also screened. Randomized controlled trials (RCTs) and single-arm trials were included, and the data were extracted according to the inclusion and exclusion criteria. Data analysis was performed using Stata (16.0) software.
Results
A total of 5850 patients in 11 RCTs and 6 single-arm trial studies involving neoadjuvant and/or adjuvant immune checkpoint inhibitor (ICI)-based therapies were included. Regarding neoadjuvant therapy, the overall complication rate after surgery reached 35% (95% CI, 0.21-0.49). Higher rates of pathological complete response (OR = 7.83; 95% CI, 5.95-10.31; P < .001) and major pathological response (OR = 5.13; 95% CI, 3.56-7.40; P < .001) were found in the resectable NSCLC patients who received neoadjuvant therapy with ICIs combined with chemotherapy compared with patients treated with chemotherapy alone. Of note, compared with chemotherapy, neoadjuvant ICIs combined with chemotherapy significantly improved the overall survival (OS) (HR = 0.65; 95% CI, 0.52-0.82; P < .001) and event-free survival (EFS) (HR = 0.59; 95% CI, 0.52-0.67; P < .001) in patients with resectable NSCLC. Regarding adjuvant therapy, a lower risk of disease progression or death (HR = 0.78; 95% CI, 0.69-0.90; P < .001) was found in the adjuvant ICI group compared with the adjuvant chemotherapy-alone group. In terms of safety, perioperative immunotherapy combined with chemotherapy did not increase toxicity compared with chemotherapy alone.
Conclusion
In patients with resectable NSCLC, perioperative immunotherapy was safe and efficacious. Perioperative immunotherapy combined with chemotherapy improved the pathologic response and EFS/DFS/OS over chemotherapy alone without increasing toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- China Medical University, Shenyang, China.
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
- Traditional Chinese Medicine Department, Shengjing Hospital of China Medical University, Shenyang, China.
ORCID-Profile: Yanmeng Wu
Förderung
- This study was supported by grants from the 345 Talent Project of Shengjing Hospital and National Natural Science Foundation of China
Zitieren
APA
Wu, Y., Hu, L., Zhang, S., & Zhang, H. (2024). The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241258164
Vancouver
Wu Y, Hu L, Zhang S, Zhang H. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241258164
BibTeX
@article{Wu2024,
author = {Wu, Yanmeng and Hu, Lin and Zhang, Shuling and Zhang, Hui},
title = {The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241258164}
}
EUVIMED